Last €36.37 EUR
Change Today -0.85 / -2.28%
Volume 50.0
MYL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 7:29 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

mylan inc (MYL) Snapshot

Open
€36.46
Previous Close
€37.22
Day High
€36.46
Day Low
€36.37
52 Week High
03/5/14 - €41.98
52 Week Low
08/28/13 - €25.80
Market Cap
13.6B
Average Volume 10 Days
268.8
EPS TTM
--
Shares Outstanding
374.0M
EX-Date
07/17/07
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MYLAN INC (MYL)

mylan inc (MYL) Details

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch form, as well as active pharmaceutical ingredients (APIs). This segment is also involved in developing APIs with non-infringing processes to partner with manufacturers; and the manufacture and sale of injectable products in the therapeutic areas of antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular. In addition, it produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector for the treatment of severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. It also offers ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. to develop, manufacture, distribute and market generic drugs in Japan. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

20,000 Employees
Last Reported Date: 02/27/14
Founded in 1961

mylan inc (MYL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
President, Director and Member of Science & T...
Total Annual Compensation: $840.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2013.

mylan inc (MYL) Key Developments

Mylan, Inc. Announces the Approval of 750 Milligram Doses of its Potassium Chloride Extended-Release Tablets from U.S. Food and Drug Administration

Mylan Inc. was steady in Friday's pre-market and the generics drug-maker saying U.S. regulators have approved the company's Abbreviated New Drug Application for its milligram and 750 milligram doses of its potassium chloride extended-release tablets, which is the generic version of Upsher-Smith's Klor-Con medication. The U.S. Food and Drug Administration has approved the new drug as a treatment for patients with hypokalemia, a condition marked by low concentrations of potassium in the bloodstream.

Mylan Launches First Generic Klor-Con Extended-Release Tablets

Mylan Inc. announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), which is the generic version of Upsher-Smith's Klor-Con(R). Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. Mylan has begun shipping this product. Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), had U.S. sales of approximately $135.05 million for the 12 months ending June 30, 2014, according to IMS Health. Currently, Mylan has 294 ANDAs pending FDA approval representing $105.7 billion in annual brand sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $25.0 billion in annual brand sales, for the 12 months ending Dec. 31, 2013.

Mylan Launches New Dexmedetomidine Hydrochoride Injection

Mylan introduced its new dexmedetomidine hydrochoride injection, 100 mcg (base) /mL. The company has launched the product after receiving final approval from the US Food and Drug Administration for the product's Abbreviated New Drug Application. It has commenced shipping of the new product, which is the therapeutically equivalent version of Precedex Injection.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:GR €36.37 EUR -0.85

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Omnicare Inc $63.59 USD -0.01
Perrigo Co PLC $148.82 USD +0.70
UCB SA €74.53 EUR +0.03
WW Grainger Inc $246.00 USD -2.79
WESCO International Inc $83.68 USD +0.34
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 33.0x
Price/Sales 2.5x
Price/Book 5.4x
Price/Cash Flow 31.1x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit www.mylan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.